Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295640 | 0.89 | FAAH (0.45) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17302229 | 0.89 | FAAH (0.63) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17295643 | 0.89 | FAAH (0.45) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17295394 | 0.87 | FAAH (0.63) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17295390 | 0.87 | FAAH (0.63) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL20933003 | 0.87 | S1PR1 (0.50) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17302139 | 0.83 | MEN1 (0.59) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17302228 | 0.82 | S1PR1 (0.59) | S1PR1S1PR3FAAH | |
| SCHEMBL17295290 | 0.82 | S1PR1 (0.50) | S1PR1S1PR3FAAHMEN1ALDH1A1 | |
| SCHEMBL17295292 | 0.82 | S1PR1 (0.50) | S1PR1S1PR3FAAHMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119265-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | S1PR1 1449/4885S1PR3 1366/4885FAAH 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.